{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"15"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"377"}],"units":"Participants"}],"description":"The immunogenicity titer is reported for samples confirmed positive for the presence of anti tremelimumab antibodies.","groups":[{"description":"Placebo.","id":"OG000","title":"PLACEBO"},{"description":"Tremelimumab 10mg/kg","id":"OG001","title":"TREMELIMUMAB"}],"paramType":"NUMBER","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Week 5","title":"Number of Participants With Positive Anti-drug Antibodies","type":"SECONDARY","typeUnitsAnalyzed":"Participants","unitOfMeasure":"Participants"}